Are amlodipine and metoprolol safe to use during the second trimester of pregnancy?

Safety of Amlodipine and Metoprolol in Second Trimester Pregnancy

Amlodipine can be used during the second trimester with reasonable safety, though nifedipine remains preferred; metoprolol is acceptable but carries a higher risk of fetal growth restriction compared to labetalol.

Amlodipine in Second Trimester

Amlodipine is considered a reasonable second-line option during pregnancy, including the second trimester, though it has less robust evidence than nifedipine. The 2025 Circulation guidelines explicitly list amlodipine as a first-line agent for postpartum hypertension, and recent evidence supports its use during pregnancy 1.

Evidence Supporting Amlodipine Use:

• FDA labeling states that limited post-marketing data are insufficient to establish definitive risk, but animal studies at 10-20 times human doses showed no teratogenicity, though rat studies demonstrated increased intrauterine deaths and decreased litter size 2

• A 2022 meta-analysis of 17 RCTs found amlodipine was slightly more effective than nifedipine (RR 1.06,95% CI 1.01-1.10) with fewer maternal side effects (RR 0.42,95% CI 0.29-0.61), and showed no difference in pregnancy outcomes including cesarean section, premature labor, fetal growth restriction, or neonatal asphyxia 3

• A 2025 position statement from the Argentine Society of Hypertension acknowledges amlodipine's off-label use in pregnancy due to nifedipine-retard discontinuation, noting it can be considered with "lower level of evidence" 4, 5

Key Caveat:

Nifedipine (sustained-release) remains the preferred calcium channel blocker due to more extensive pregnancy safety data 1. Use amlodipine when nifedipine is unavailable, not tolerated (headaches, tachycardia, edema), or when once-daily dosing is critical for adherence.

Metoprolol in Second Trimester

Metoprolol is acceptable during the second trimester but carries a documented risk of fetal growth restriction that exceeds other beta-blockers like labetalol.

Evidence on Metoprolol:

• The 2020 European Heart Journal guidelines explicitly state that "metoprolol is considered safe for breastfeeding mothers" 6, implying acceptable safety during pregnancy, though labetalol and nifedipine are listed as first-line for hypertensive emergencies

• FDA labeling reports that metoprolol showed effects on spermatogenesis in rats and increased postimplantation loss at doses 11 times the human dose, but there are no adequate human studies 7

• A 2020 cohort study of 294 neonates exposed to metoprolol/bisoprolol during second/third trimesters found:

  • 24.1% were small-for-gestational-age vs. 10.2% with methyldopa (OR 2.5,95% CI 1.2-5.2) and 9.9% in non-hypertensive controls (OR 4.3,95% CI 2.6-7.1)
  • Increased preterm birth risk vs. non-hypertensive pregnancies (OR 2.2,95% CI 1.3-3.8)
  • Neonatal adverse outcomes occurred in 11.5% but without statistical significance compared to controls 8

• A 2010 case-control study found selective beta-blockers increased SGA risk (OR 6.00,95% CI 1.06-33.87) 9

Critical Distinction:

Labetalol (combined alpha-beta blocker) is strongly preferred over metoprolol as first-line therapy during pregnancy 1. The 2025 Circulation guidelines emphasize labetalol's minimal risks despite potential for fetal bradycardia and hypoglycemia, with no teratogenicity reported 1.

Avoid atenolol entirely—it carries the highest risk of fetal growth restriction among beta-blockers 1.

Clinical Algorithm for Second Trimester Hypertension

1. First-line choices (in order of preference):

   • Labetalol (unless reactive airway disease present)
   • Nifedipine sustained-release
   • Methyldopa (if available and tolerated)

2. Second-line/alternative options:

   • Amlodipine: When nifedipine unavailable or not tolerated; offers once-daily dosing advantage
   • Metoprolol: When labetalol contraindicated (asthma/COPD) AND close fetal growth monitoring available

3. Monitor closely if using metoprolol:

   • Serial ultrasounds for fetal growth every 3-4 weeks
   • Umbilical artery Doppler if growth concerns arise
   • Neonatal glucose and heart rate monitoring at delivery

4. Absolute contraindications:

   • ACE inhibitors and ARBs (teratogenic) 1
   • Atenolol (fetal growth restriction) 1

Important Caveats

• Maternal hypertension itself contributes to fetal growth restriction, making it difficult to isolate drug effects from disease effects 8
• Combination therapy may be needed; labetalol can be combined with nifedipine or amlodipine for uncontrolled BP 1
• Severe hypertension (≥160/110 mmHg) requires immediate treatment within 30-60 minutes to prevent maternal stroke and pulmonary edema 1, 6
• If using amlodipine with magnesium sulfate for seizure prophylaxis, monitor closely for hypotension due to potential synergism between calcium channel blockers and magnesium 6